Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-925 in OSA with Excessive Daytime Sleepiness
NCT04091425Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in obstructive sleep apnea (OSA) (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Percentage of Participants who Experience at Least One Treatment Emergent Adverse Event up to 43 days, Percentage of Participants who Meet the Markedly Abnormal Criteria for Clinical Safety Laboratory Tests up to 43 days and 2 more. Started Nov 2019; status: completed.
02
Drugs
danavorexton
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04091425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091425.